Axillary management in patients with breast cancer and positive axilla at diagnosis. Experience in a Spanish university hospital with a 5-year follow-up
Background: Axillary lymph node dissection (ALND) was the standard in breast cancer with axillary involvement until recently. Along with the number of metastatic nodes, axillary positivity was considered a main prognostic factor and scientific evidence shows that the administration of radiotherapy o...
| Autores: | , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Universitat Pompeu Fabra |
| Repositorio: | Repositorio Digital de la UPF |
| OAI Identifier: | oai:repositori.upf.edu:10230/59356 |
| Acceso en línea: | http://hdl.handle.net/10230/59356 http://dx.doi.org/10.4103/jcrt.jcrt_263_22 |
| Access Level: | acceso abierto |
| Palabra clave: | Axilla Axillary dissection Breast neoplasms Follow-up studies Lymph nodes Lymphatic metastases Neoadjuvant therapy Sentinel lymph node biopsy |
| id |
ES_940ccd72c6dfd02bfe8570318ed4df3f |
|---|---|
| oai_identifier_str |
oai:repositori.upf.edu:10230/59356 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| spelling |
Axillary management in patients with breast cancer and positive axilla at diagnosis. Experience in a Spanish university hospital with a 5-year follow-upJiménez Gómez, MartaLoro-Pérez, JorgeVega Benítez, VictorHernández Hernández, Juan RamónArgudo Aguirre, NuriaAxillaAxillary dissectionBreast neoplasmsFollow-up studiesLymph nodesLymphatic metastasesNeoadjuvant therapySentinel lymph node biopsyBackground: Axillary lymph node dissection (ALND) was the standard in breast cancer with axillary involvement until recently. Along with the number of metastatic nodes, axillary positivity was considered a main prognostic factor and scientific evidence shows that the administration of radiotherapy on ganglion areas decreases the risk of recurrence even in positive axilla. The objective of this study was to evaluate the axillary treatment in patients with positive axilla at diagnosis, the evolution of them over time, and to assess patient's follow-up with the aim of avoiding the morbidity associated with axillary dissection. Methods: A retrospective observational study of breast cancer patients diagnosed between 2010 and 2017 was performed. In total, 1,100 patients were studied, out of which 168 were women with clinically and histologically positive axilla at diagnosis. Seventy-six percent received primary chemotherapy and subsequent treatment with sentinel node biopsy, axillary dissection, or both. Patients with positive sentinel lymph node biopsy received either radiotherapy or lymphadenectomy depending on the year time they were diagnosed. Results: For 60 patients out of 168, neoadjuvant chemotherapy resulted in a complete pathological axillary response. Axillary recurrence was registered for six patients. No recurrence was detected in the biopsy group associated with radiotherapy. These results support the benefit of lymph node radiotherapy for patients with positive sentinel node biopsy after receiving primary chemotherapy. Conclusion: Sentinel node biopsy provides useful and reliable information about cancer staging and might prevent lymphadenectomy, leading to a decrease in morbidity. Pathological response to systemic treatment came out as the most important predictive factor of disease-free survival of breast cancer.Wolters Kluwer (LWW)202420242023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/59356http://dx.doi.org/10.4103/jcrt.jcrt_263_22reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésJ Cancer Res Ther. 2023 Jan-Mar;19(2):183-90© 2022 Journal of Cancer Research and Therapeutics. This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 4.0 Unported (https://creativecommons.org/licenses/by-nc-sa/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.http://creativecommons.org/licenses/by-nc-sa/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/593562026-06-12T07:21:37Z |
| dc.title.none.fl_str_mv |
Axillary management in patients with breast cancer and positive axilla at diagnosis. Experience in a Spanish university hospital with a 5-year follow-up |
| title |
Axillary management in patients with breast cancer and positive axilla at diagnosis. Experience in a Spanish university hospital with a 5-year follow-up |
| spellingShingle |
Axillary management in patients with breast cancer and positive axilla at diagnosis. Experience in a Spanish university hospital with a 5-year follow-up Jiménez Gómez, Marta Axilla Axillary dissection Breast neoplasms Follow-up studies Lymph nodes Lymphatic metastases Neoadjuvant therapy Sentinel lymph node biopsy |
| title_short |
Axillary management in patients with breast cancer and positive axilla at diagnosis. Experience in a Spanish university hospital with a 5-year follow-up |
| title_full |
Axillary management in patients with breast cancer and positive axilla at diagnosis. Experience in a Spanish university hospital with a 5-year follow-up |
| title_fullStr |
Axillary management in patients with breast cancer and positive axilla at diagnosis. Experience in a Spanish university hospital with a 5-year follow-up |
| title_full_unstemmed |
Axillary management in patients with breast cancer and positive axilla at diagnosis. Experience in a Spanish university hospital with a 5-year follow-up |
| title_sort |
Axillary management in patients with breast cancer and positive axilla at diagnosis. Experience in a Spanish university hospital with a 5-year follow-up |
| dc.creator.none.fl_str_mv |
Jiménez Gómez, Marta Loro-Pérez, Jorge Vega Benítez, Victor Hernández Hernández, Juan Ramón Argudo Aguirre, Nuria |
| author |
Jiménez Gómez, Marta |
| author_facet |
Jiménez Gómez, Marta Loro-Pérez, Jorge Vega Benítez, Victor Hernández Hernández, Juan Ramón Argudo Aguirre, Nuria |
| author_role |
author |
| author2 |
Loro-Pérez, Jorge Vega Benítez, Victor Hernández Hernández, Juan Ramón Argudo Aguirre, Nuria |
| author2_role |
author author author author |
| dc.subject.none.fl_str_mv |
Axilla Axillary dissection Breast neoplasms Follow-up studies Lymph nodes Lymphatic metastases Neoadjuvant therapy Sentinel lymph node biopsy |
| topic |
Axilla Axillary dissection Breast neoplasms Follow-up studies Lymph nodes Lymphatic metastases Neoadjuvant therapy Sentinel lymph node biopsy |
| description |
Background: Axillary lymph node dissection (ALND) was the standard in breast cancer with axillary involvement until recently. Along with the number of metastatic nodes, axillary positivity was considered a main prognostic factor and scientific evidence shows that the administration of radiotherapy on ganglion areas decreases the risk of recurrence even in positive axilla. The objective of this study was to evaluate the axillary treatment in patients with positive axilla at diagnosis, the evolution of them over time, and to assess patient's follow-up with the aim of avoiding the morbidity associated with axillary dissection. Methods: A retrospective observational study of breast cancer patients diagnosed between 2010 and 2017 was performed. In total, 1,100 patients were studied, out of which 168 were women with clinically and histologically positive axilla at diagnosis. Seventy-six percent received primary chemotherapy and subsequent treatment with sentinel node biopsy, axillary dissection, or both. Patients with positive sentinel lymph node biopsy received either radiotherapy or lymphadenectomy depending on the year time they were diagnosed. Results: For 60 patients out of 168, neoadjuvant chemotherapy resulted in a complete pathological axillary response. Axillary recurrence was registered for six patients. No recurrence was detected in the biopsy group associated with radiotherapy. These results support the benefit of lymph node radiotherapy for patients with positive sentinel node biopsy after receiving primary chemotherapy. Conclusion: Sentinel node biopsy provides useful and reliable information about cancer staging and might prevent lymphadenectomy, leading to a decrease in morbidity. Pathological response to systemic treatment came out as the most important predictive factor of disease-free survival of breast cancer. |
| publishDate |
2023 |
| dc.date.none.fl_str_mv |
2023 2024 2024 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/10230/59356 http://dx.doi.org/10.4103/jcrt.jcrt_263_22 |
| url |
http://hdl.handle.net/10230/59356 http://dx.doi.org/10.4103/jcrt.jcrt_263_22 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
J Cancer Res Ther. 2023 Jan-Mar;19(2):183-90 |
| dc.rights.none.fl_str_mv |
http://creativecommons.org/licenses/by-nc-sa/4.0/ info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-sa/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
Wolters Kluwer (LWW) |
| publisher.none.fl_str_mv |
Wolters Kluwer (LWW) |
| dc.source.none.fl_str_mv |
reponame:Repositorio Digital de la UPF instname:Universitat Pompeu Fabra |
| instname_str |
Universitat Pompeu Fabra |
| reponame_str |
Repositorio Digital de la UPF |
| collection |
Repositorio Digital de la UPF |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869413647099363328 |
| score |
15,811543 |